Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Jazz Pharmaceuticals
Biotech
ESMO: Jazz HER2 bispecific posts 59% survival at 30 months
The 30-month data unveiled at ESMO gave other insights into zanidatamab’s efficacy, including a confirmed objective response rate of 84%.
James Waldron
Sep 16, 2024 3:00am
Jazz's ph. 2 essential tremor test misses endpoint
Jun 20, 2024 9:30am
ASCO: It's back to the basics for cancer drug developers
Jun 5, 2024 10:55am
ASCO: Jazz shares 'unprecedented' biliary tract cancer data
Jun 1, 2024 11:11am
John Cox gets new biotech CEO gig at Dyne—Chutes & Ladders
Mar 29, 2024 9:30am
Jazz jumps into KRAS G12D space via $10M upfront deal with Redx
Feb 7, 2024 8:30am